Financial Data and Key Metrics Changes - In Q4 2021, research and development expenses were $14.4 million, up from $6.4 million in Q4 2020, primarily due to increased employee count and product development activities [44] - Selling, general and administrative expenses in Q4 2021 were $13.4 million compared to $3.2 million in Q4 2020, driven by additional employees and stock-based compensation [45] - Total operating expenses in Q4 2021 were $27.8 million, up from $9.5 million in Q4 2020, with a net loss of $29.4 million compared to a loss of $9.5 million in Q4 2020 [46] - As of December 31, 2021, the company had $471.3 million in cash, cash equivalents, and marketable securities, providing a strong cash position for continued investment [47] Business Line Data and Key Metrics Changes - The company has focused on commercializing its next-generation protein sequencing platform, with significant progress in scaling operations and securing supply chains [33][34] - The integration of Majelac Technologies has enhanced chip assembly and packaging capabilities, supporting the commercial launch [34] Market Data and Key Metrics Changes - The proteomics sector is experiencing transformative growth, with Quantum-Si positioned uniquely as the only company seeking to commercialize digital, sequencing-based protein sequencing [15][17] - The company aims to leverage opportunities in immunology and long COVID as catalysts for the adoption of its technology [13][20] Company Strategy and Development Direction - The company is focused on commercializing its next-generation protein sequencing technology, with a clear goal for 2022 to establish its presence in the market [12][13] - A new Scientific Advisory Board has been established to identify high-impact applications of single molecule protein sequencing across various fields [14] - The company aims to position itself at the intersection of multiple scientific disciplines to enable a digital transformation in the $50 billion proteomics market [50] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of understanding biology and the immune system, particularly in the context of COVID-19, as a driver for the adoption of their technology [13][20] - The company is optimistic about its future, citing a strong cash position and an experienced team as key factors for success [52] Other Important Information - The company plans to launch and commercialize its protein sequencing system in the second half of 2022, with significant hiring and product development initiatives underway [48] - Non-GAAP operating expenses are expected to grow by 70% to 80% year-over-year in 2022 as the company prepares for commercialization [48] Q&A Session Summary Question: How many orders are currently in place for the system, and what is the likelihood of fulfilling those orders in 2022? - The company has identified over 1,000 potential customers, with 600 focused on protein sequencing, and is well-positioned to deliver to those most likely to lead to mass adoption [57] Question: What are the next steps before the early access program? - The focus is on publishing white papers and establishing the technology as a go-to tool for research and biomarker discovery [63] Question: How long until clinical applications can be realized? - Early clinical applications are expected to emerge in the coming few years, with a focus on targeted applications [70] Question: What is the expected revenue generation in 2022? - While specific revenue guidance is not provided, the company is positioned for significant growth, with a strong cash position and experienced team [73][82]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or 530 Old Whitfield Street Guilford, Connecticut 06437 (Address of principal executive offices) (Zip Code) (203) 458-7100 (Registrant's telephone number, including area code) Not applicable (Former name, former address and former fiscal year, if changed since last report) Secur ...

Quantum-Si Incorporated (NASDAQ:QSI) Q3 2021 Earnings Conference Call November 11, 2021 8:30 AM ET Company Participants Juan Avendano – Vice President-Investor Relations John Stark – Chief Executive Officer Claudia Drayton – Chief Financial Officer Conference Call Participants Kyle Mikson – Canaccord Genuity Operator Hello, and welcome to the Quantum-Si Q3 2021 Earnings Call. My name is Boben [ph] and I will be coordinating your call today. [Operator Instructions] I will now hand you over to your host, Juan ...

Quantum-Si incorporated (NASDAQ:QSI) Q2 2021 Earnings Conference Call August 16, 2021 4:30 PM ET Company Participants Mike Cavanaugh – Investor Relations John Stark – Chief Executive Officer Claudia Drayton – Chief Financial Officer Conference Call Participants Kyle Mikson – Canaccord Genuity Operator Hello and thank you for standing by and welcome to the Quantum-Si Second Quarter 2021 Earnings Call. All lines will be muted during the presentation portion of the call with an opportunity for questions and an ...

Part I – Financial Information [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) Presents Quantum-Si's unaudited condensed consolidated financial statements, covering balance sheets, operations, equity, cash flows, and notes [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) | Metric | June 30, 2021 (in thousands) | December 31, 2020 (in thousands) | | :----- | :--------------------------- | :------------------------------- | | Cash and cash equivalents | $521,936 | $36,910 | | Total current assets | $524,093 | $37,858 | | Total assets | $526,950 | $40,592 | | Total current liabilities | $7,864 | $2,754 | | Warrant liabilities | $15,150 | $- | | Total liabilities | $23,014 | $4,503 | | Total stockholders' equity (deficit) | $503,936 | $(159,725) | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) | Metric (in thousands) | Three months ended June 30, 2021 | Three months ended June 30, 2020 | Six months ended June 30, 2021 | Six months ended June 30, 2020 | | :-------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and development | $13,114 | $6,595 | $21,086 | $14,519 | | General and administrative | $17,805 | $1,306 | $21,222 | $3,526 | | Sales and marketing | $1,245 | $300 | $1,635 | $559 | | Total operating expenses | $32,164 | $8,201 | $43,943 | $18,604 | | Loss from operations | $(32,164) | $(8,201) | $(43,943) | $(18,604) | | Change in fair value of warrant liabilities | $(3,533) | $- | $(3,533) | $- | | Net loss and comprehensive loss | $(35,697) | $(8,197) | $(47,476) | $(18,511) | | Net loss per common share, basic and diluted | $(3.05) | $(1.53) | $(5.50) | $(3.46) | [Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Convertible%20Preferred%20Stock%20and%20Stockholders%27%20Equity%20(Deficit)) | Metric (in thousands) | Balance - December 31, 2020 | Balance - June 30, 2021 | | :-------------------- | :-------------------------- | :---------------------- | | Convertible preferred stock | $195,814 | $- | | Class A common stock | $1 | $12 | | Class B common stock | $- | $2 | | Additional paid-in capital | $12,517 | $723,641 | | Accumulated deficit | $(172,243) | $(219,719) | | Total stockholders' equity (deficit) | $(159,725) | $503,936 | - Conversion of **90,789,268 shares** of convertible preferred stock into Class A and Class B common stock, valued at **$195,810 thousand**[22](index=22&type=chunk) - Net equity infusion from the Business Combination of **$501,172 thousand**[22](index=22&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) | Metric (in thousands) | Six months ended June 30, 2021 | Six months ended June 30, 2020 | | :-------------------- | :----------------------------- | :----------------------------- | | Net cash used in operating activities | $(29,875) | $(17,192) | | Net cash used in investing activities | $(1,229) | $(332) | | Net cash provided by financing activities | $516,130 | $11,150 | | Net increase (decrease) in cash and cash equivalents | $485,026 | $(6,374) | | Cash and cash equivalents at end of period | $521,936 | $26,556 | - Net proceeds from equity infusion from the Business Combination amounted to **$514,187 thousand** in 2021[25](index=25&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Provides detailed explanations and disclosures for financial statements, covering organization, accounting policies, Business Combination, fair value, and key accounts [1. Organization and Description of Business](index=8&type=section&id=1.%20Organization%20and%20Description%20of%20Business) - Quantum-Si Incorporated (formerly HighCape Capital Acquisition Corp.) completed a business combination on **June 10, 2021**, with Legacy Quantum-Si becoming a wholly-owned subsidiary[27](index=27&type=chunk) - The company's mission is to transform single molecule analysis and democratize access to the proteome using its proprietary universal single molecule detection platform for Next Generation Protein Sequencing (NGPS)[28](index=28&type=chunk) - The NGPS platform includes the Carbon™ automated sample preparation instrument, Platinum™ NGPS instrument, Quantum-Si Cloud™ software service, and reagent kits and chips[28](index=28&type=chunk) [2. Summary of Significant Accounting Policies](index=8&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) - The condensed consolidated financial statements are prepared in accordance with U.S. GAAP and SEC interim reporting rules, reflecting all normal recurring adjustments[30](index=30&type=chunk)[32](index=32&type=chunk) - The COVID-19 pandemic has adversely impacted operations, personnel, supply chain, and hiring, but no significant impairment losses on assets have been incurred[34](index=34&type=chunk)[36](index=36&type=chunk) - Warrants are classified as long-term liabilities at fair value, with changes recognized in the statements of operations, due to criteria under ASC 815-40[40](index=40&type=chunk) [3. Business Combination](index=10&type=section&id=3.%20Business%20Combination) - The Business Combination, completed on **June 10, 2021**, was accounted for as a reverse recapitalization, with Legacy Quantum-Si stockholders retaining control[45](index=45&type=chunk)[46](index=46&type=chunk) - The transaction resulted in a significant increase in cash of **$540,276 thousand**, offset by transaction costs and other payments, leading to an equity infusion of **$501,172 thousand**[56](index=56&type=chunk)[57](index=57&type=chunk) - A dual-class stock structure was adopted, with Class B common stock having **20 votes per share**, giving Dr. Rothberg approximately **80.4%** of the combined voting power and making the company a 'controlled company'[50](index=50&type=chunk)[54](index=54&type=chunk) [4. Fair Value of Financial Instruments](index=12&type=section&id=4.%20Fair%20Value%20of%20Financial%20Instruments) - Fair value measurements are categorized into a three-tier hierarchy: Level 1 (quoted prices in active markets), Level 2 (observable inputs), and Level 3 (unobservable inputs)[59](index=59&type=chunk)[60](index=60&type=chunk) | Asset/Liability (in thousands) | Total Fair Value (June 30, 2021) | Level 1 | Level 2 | Level 3 | | :----------------------------- | :------------------------------- | :------ | :------ | :------ | | Money market accounts | $518,051 | $518,051 | $- | $- | | Warrant liabilities - Public Warrants | $14,413 | $14,413 | $- | $- | | Warrant liabilities - Private Warrants | $737 | $- | $- | $737 | | Total assets at fair value | $518,051 | $518,051 | $- | $- | | Total liabilities at fair value | $15,150 | $14,413 | $- | $737 | - Private Warrants are valued using a binomial lattice model with a volatility of **49.0%**, risk-free rate of **0.86%**, strike price of **$11.50**, common stock fair value of **$12.26**, and expected life of **4.9 years**[62](index=62&type=chunk) [5. Property and Equipment, Net](index=13&type=section&id=5.%20Property%20and%20Equipment,%20Net) | Category (in thousands) | June 30, 2021 | December 31, 2020 | | :---------------------- | :------------ | :---------------- | | Laboratory equipment | $5,322 | $4,245 | | Computer equipment | $903 | $765 | | Software | $156 | $136 | | Furniture and fixtures | $47 | $47 | | Construction in process | $109 | $35 | | Less: Accumulated depreciation | $(3,680)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39486 HIGHCAPE CAPITAL ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 85-1388175 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39486 HighCape Capital Acquisition Corp. (Exact name of registrant as specified in its charter) | Delaware | 85-1388175 | | --- | --- | | (State o ...

PART I [Condensed Financial Statements](index=4&type=section&id=Item%201.%20Condensed%20Financial%20Statements) Presents HighCape Capital Acquisition Corp.'s unaudited condensed financial statements as of September 30, 2020, reflecting its formation and IPO as a blank check company [Condensed Balance Sheet](index=4&type=section&id=Condensed%20Balance%20Sheet) The September 30, 2020 balance sheet shows total assets of $116.3 million, primarily cash in the Trust Account, and total liabilities of $4.1 million Condensed Balance Sheet as of September 30, 2020 | Category | Amount (USD) | | :--- | :--- | | **Total Assets** | **$116,339,712** | | Cash and cash equivalents held in Trust Account | $115,000,384 | | Cash | $1,164,723 | | **Total Liabilities** | **$4,113,342** | | Deferred underwriting fee payable | $4,025,000 | | **Class A common stock subject to possible redemption** | **$107,226,360** | | **Total Stockholders' Equity** | **$5,000,010** | [Condensed Statement of Operations](index=5&type=section&id=Condensed%20Statement%20of%20Operations) The company reported a net loss of $50,253 for Q3 2020 and $51,253 from inception to September 30, 2020, primarily due to administrative expenses Statement of Operations Highlights (Unaudited) | Period | Net Loss (USD) | | :--- | :--- | | Three Months Ended Sep 30, 2020 | $(50,253) | | Inception (Jun 10, 2020) to Sep 30, 2020 | $(51,253) | [Condensed Statement of Changes in Stockholders' Equity](index=6&type=section&id=Condensed%20Statement%20of%20Changes%20in%20Stockholders%20Equity) Stockholders' equity increased to **$5.0 million** from inception to September 30, 2020, driven by IPO and private placement proceeds - Total stockholders' equity reached **$5,000,010** as of September 30, 2020, following the IPO, private placement, and accounting for stock redemptions and net loss[15](index=15&type=chunk) [Condensed Statement of Cash Flows](index=7&type=section&id=Condensed%20Statement%20of%20Cash%20Flows) Net cash provided by financing activities was **$116.3 million**, with **$115.0 million** used in investing, resulting in a **$1.16 million** cash balance Cash Flow Summary (Inception to Sep 30, 2020) | Cash Flow Activity | Amount (USD) | | :--- | :--- | | Net cash used in operating activities | $(182,900) | | Net cash used in investing activities | $(115,000,000) | | Net cash provided by financing activities | $116,347,623 | | **Net Change in Cash** | **$1,164,723** | [Notes to Condensed Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Financial%20Statements) Detailed notes explain the company's SPAC status, IPO terms, private placement, related-party transactions, and financial commitments - The Company is a blank check company formed to effect a business combination and will have until September 9, 2022 (24 months from the IPO closing) to complete one[20](index=20&type=chunk)[33](index=33&type=chunk) - On September 9, 2020, the Company consummated its IPO of **11,500,000 units** at **$10.00 per unit**, generating gross proceeds of **$115,000,000**[22](index=22&type=chunk)[23](index=23&type=chunk) - Simultaneously, it sold **405,000 private placement units** to the Sponsor for **$4,050,000**[22](index=22&type=chunk)[23](index=23&type=chunk) - Following the IPO, **$115,000,000** of the net proceeds was placed in a trust account, which will be invested in U.S. government securities[25](index=25&type=chunk) - The underwriters are entitled to a deferred underwriting fee of **$4,025,000**, payable from the Trust Account only upon the completion of a Business Combination[68](index=68&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The MD&A details the company's blank check status, net loss, liquidity from IPO and private placement, and limited contractual obligations - The company is a blank check company with no operations to date; its activities have been limited to organizational matters and preparing for its IPO[95](index=95&type=chunk)[97](index=97&type=chunk) Results of Operations | Period | Net Loss (USD) | Description | | :--- | :--- | :--- | | Q3 2020 | $50,253 | Consists of $50,637 in operating costs, offset by $384 in interest income | | Inception to Sep 30, 2020 | $51,253 | Consists of $51,637 in operating costs, offset by $384 in interest income | Liquidity and Capital Resources as of Sep 30, 2020 | Category | Amount (USD) | Purpose | | :--- | :--- | :--- | | Cash held in Trust Account | $115,000,384 | To be used for an initial Business Combination | | Cash held outside Trust Account | $1,164,723 | To be used for identifying and evaluating target businesses and working capital | - Contractual obligations are limited to a monthly fee of up to **$10,000** to an affiliate of the Sponsor for administrative support and a deferred underwriting fee of **$4,025,000** payable upon completion of a Business Combination[109](index=109&type=chunk)[110](index=110&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=27&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company has minimal market or interest rate risk due to trust account investments in short-term U.S. government securities - The company has minimal market and interest rate risk as funds in the Trust Account are invested in short-term U.S. government treasury securities or money market funds[115](index=115&type=chunk) [Controls and Procedures](index=27&type=section&id=Item%204.%20Control%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2020, with no material changes to internal controls - As of September 30, 2020, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[117](index=117&type=chunk) - There were no material changes in the company's internal control over financial reporting during the most recently completed fiscal quarter[118](index=118&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=29&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no legal proceedings - The company has no legal proceedings to report[120](index=120&type=chunk) [Risk Factors](index=29&type=section&id=Item%201A.%20Risk%20Factors) No material changes to previously disclosed risk factors from the September 4, 2020 IPO prospectus have occurred - There have been no material changes to the risk factors disclosed in the company's final IPO prospectus dated September 4, 2020[121](index=121&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=29&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Details proceeds from the IPO (**$115 million**) and private placement (**$4.05 million**), including allocation to the Trust Account and underwriting fees - The IPO of **11,500,000 units** at **$10.00 per unit** on September 9, 2020, generated gross proceeds of **$115,000,000**[122](index=122&type=chunk) - A simultaneous private placement of **405,000 units** to the Sponsor at **$10.00 per unit** generated total proceeds of **$4,050,000**[123](index=123&type=chunk) - Of the gross proceeds, **$115,000,000** was placed in the Trust Account[124](index=124&type=chunk) - The company paid **$2,300,000** in underwriting fees and deferred an additional **$4,025,000**[124](index=124&type=chunk) [Defaults Upon Senior Securities](index=29&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - The company has no defaults upon senior securities to report[126](index=126&type=chunk) [Mine Safety Disclosures](index=29&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Mine safety disclosures are not applicable to the company - Mine safety disclosures are not applicable to the company's business[127](index=127&type=chunk) [Other Information](index=29&type=section&id=Item%205.%20Other%20Information) No other information is reported for the period - There is no other information to report for the period[128](index=128&type=chunk) [Exhibits](index=29&type=section&id=Item%206.%20Exhibits) Lists key exhibits filed with the Form 10-Q, including legal and financial agreements related to the company's formation and IPO - The report includes several key exhibits, such as the Underwriting Agreement, Warrant Agreement, Investment Management Trust Agreement, and Registration Rights Agreement[131](index=131&type=chunk)